News | November 15, 2023
Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
The company is confident of addressing all the observations within the stipulated time
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Subscribe To Our Newsletter & Stay Updated
